BRPI9912663B8 - vacina contra cáncer e polipeptìdeo. - Google Patents

vacina contra cáncer e polipeptìdeo.

Info

Publication number
BRPI9912663B8
BRPI9912663B8 BRPI9912663A BRPI9912663B8 BR PI9912663 B8 BRPI9912663 B8 BR PI9912663B8 BR PI9912663 A BRPI9912663 A BR PI9912663A BR PI9912663 B8 BRPI9912663 B8 BR PI9912663B8
Authority
BR
Brazil
Prior art keywords
polypeptide
vaccine against
against cancer
vaccine
cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Haruo Sugiyama
Yoshihiro Oka
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16714530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9912663(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of BRPI9912663A publication Critical patent/BRPI9912663A/pt
Publication of BRPI9912663B1 publication Critical patent/BRPI9912663B1/pt
Publication of BRPI9912663B8 publication Critical patent/BRPI9912663B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
BRPI9912663 1998-07-31 1999-07-30 vacina contra cáncer e polipeptìdeo. BRPI9912663B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21809398 1998-07-31
PCT/JP1999/004130 WO2000006602A1 (fr) 1998-07-31 1999-07-30 Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1

Publications (3)

Publication Number Publication Date
BRPI9912663A BRPI9912663A (pt) 2001-05-02
BRPI9912663B1 BRPI9912663B1 (pt) 2011-05-31
BRPI9912663B8 true BRPI9912663B8 (pt) 2021-07-06

Family

ID=16714530

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9912663 BRPI9912663B8 (pt) 1998-07-31 1999-07-30 vacina contra cáncer e polipeptìdeo.

Country Status (15)

Country Link
US (7) US7030212B1 (pt)
EP (3) EP2280031B1 (pt)
JP (2) JP4422903B2 (pt)
KR (1) KR100767554B1 (pt)
CN (4) CN1560078B (pt)
AT (1) ATE420112T1 (pt)
AU (1) AU4932199A (pt)
BR (1) BRPI9912663B8 (pt)
CA (1) CA2337743C (pt)
DE (1) DE69940264D1 (pt)
DK (1) DK1103564T3 (pt)
ES (1) ES2318898T3 (pt)
HK (4) HK1036073A1 (pt)
PT (1) PT1103564E (pt)
WO (1) WO2000006602A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
PT1103564E (pt) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
AU2001247220A1 (en) * 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
KR100863853B1 (ko) * 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
JP4229832B2 (ja) * 2001-06-29 2009-02-25 忠範 真弓 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原とカチオン性リポソームとを含んで成る癌ワクチン
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
CA2489227C (en) 2002-06-12 2012-03-13 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptides
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ES2331305T3 (es) 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
BRPI0406800B8 (pt) * 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
WO2005001117A1 (ja) 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
JP4621142B2 (ja) 2003-11-05 2011-01-26 株式会社癌免疫研究所 Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2005095598A1 (ja) * 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
CN101336249A (zh) * 2005-11-30 2008-12-31 株式会社癌免疫研究所 新型肽化合物
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
CN105664147A (zh) 2007-02-07 2016-06-15 日本电气株式会社 用于癌症的治疗剂
NZ599161A (en) 2007-02-27 2012-07-27 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
US10093977B2 (en) 2007-03-05 2018-10-09 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
RU2010127298A (ru) * 2007-12-05 2012-01-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. (Jp) Вакцинная композиция против злокачественной опухоли
BR112013008230A2 (pt) 2010-10-05 2016-06-14 Int Inst Cancer Immunology Inc método para ativar célula t auxiliar
EP3447140A3 (en) 2011-06-28 2019-05-29 International Institute of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP2792745B1 (en) * 2011-12-14 2017-11-15 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
EP2868325B1 (en) 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
BR112015013697A2 (pt) 2012-12-17 2017-11-14 Univ Osaka método para ativar célula t auxiliar
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
ES2832546T3 (es) 2013-01-15 2021-06-10 Memorial Sloan Kettering Cancer Center Péptidos WT-1 inmunogénicos y métodos de uso de los mismos
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
CN103961699B (zh) 2013-02-05 2018-11-06 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
US20140220056A1 (en) 2013-02-05 2014-08-07 Nitto Denko Corporation Vaccine composition for transdermal administration
RU2687144C2 (ru) 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения
RU2014102941A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
ES2694328T3 (es) * 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
KR102121638B1 (ko) * 2013-03-29 2020-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Wt1 항원 펩티드 콘쥬게이트 백신
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
CA2956545A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
CA2962630C (en) 2014-09-27 2023-02-21 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection
CN108348552A (zh) * 2015-09-10 2018-07-31 纪念斯隆-凯特林癌症中心 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
HRP20220994T1 (hr) 2015-11-20 2022-11-11 Memorial Sloan Kettering Cancer Center Sastav za liječenje raka
EP3423086A1 (en) * 2016-03-03 2019-01-09 Institut Gustave Roussy (IGR) Ptps-based vaccines against cancer
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
US20210338587A1 (en) 2018-09-28 2021-11-04 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
CN113395976A (zh) * 2018-10-05 2021-09-14 株式会社癌免疫研究所 良性肿瘤的预防或治疗药
TW202045528A (zh) 2019-02-28 2020-12-16 日商大日本住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
EP4017872A1 (en) 2019-08-20 2022-06-29 Fred Hutchinson Cancer Center T-cell immunotherapy specific for wt-1
CA3162690A1 (en) 2019-12-31 2021-07-08 Minoru S. H. Ko Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
EP4151227A1 (en) 2020-05-12 2023-03-22 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
TW202208395A (zh) * 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
TW202315645A (zh) 2021-08-12 2023-04-16 日商癌免疫研究所股份有限公司 用以處置或預防癌症之醫藥組合物及方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6122018A (ja) 1984-07-06 1986-01-30 Green Cross Corp:The 癌免疫療法増強剤
JP2546254B2 (ja) 1987-02-23 1996-10-23 澁谷工業株式会社 ガス詰め充填装置
WO1991007509A1 (en) 1989-11-13 1991-05-30 Massachusetts Institute Of Technology Localization and characterization of the wilms's tumor gene
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CA2069541C (en) 1992-05-26 2005-02-01 Cornelis J. M. Melief Induction of an antigen-specific t-lymphocyte response
EP0741580A4 (en) 1993-12-14 2001-07-11 Univ Johns Hopkins Med CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE SUBSTANCES FOR IMMUNOTHERAPY
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AU5779696A (en) 1995-06-01 1996-12-18 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonuc leotide derivative against wilms' tumor gene (wt1)
JP3904260B2 (ja) 1995-06-01 2007-04-11 岸本 忠三 ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
PT1435205E (pt) 1995-09-19 2010-02-04 Bayer Bioscience Gmbh Plantas que sintetizam um amido modificado, processo para a sua produção e amido modificado
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
JPH09191635A (ja) 1996-01-05 1997-07-22 Toshio Aida モータ
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US20030092656A1 (en) 1997-07-16 2003-05-15 Haruo Sugiyama Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
US5985264A (en) 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
PT1103564E (pt) * 1998-07-31 2009-03-13 Int Inst Cancer Immunology Inc Antigénios de cancro com base no produto do gene supressor de tumor wt1
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AR021849A1 (es) 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030215458A1 (en) 1998-09-30 2003-11-20 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
PL349347A1 (en) 1999-01-12 2002-07-15 Smithkline Beecham Biolog Novel treatment
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
JP2001089389A (ja) 1999-07-22 2001-04-03 Sumitomo Pharmaceut Co Ltd 抗原特異的ｔ細胞の誘導剤
ATE320266T1 (de) 1999-07-22 2006-04-15 Dainippon Sumitomo Pharma Co Induktion von antigen-spezifischen t-zellen durch interferon
AU2001247220A1 (en) 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
KR100863853B1 (ko) 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
EP1447092A4 (en) 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
EP1447091A4 (en) 2001-09-28 2008-02-13 Institute Of Can International NEW METHOD FOR INDUCTION OF ANTIGEN SPECIFIC T CELLS
CA2489227C (en) 2002-06-12 2012-03-13 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptides
WO2004024175A1 (ja) 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ES2331305T3 (es) 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
BRPI0406800B8 (pt) 2003-01-15 2021-05-25 Chugai Seiyaku Kk Chugai Pharmaceutical Co Ltd "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
WO2005001117A1 (ja) 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
JP4621142B2 (ja) 2003-11-05 2011-01-26 株式会社癌免疫研究所 Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
WO2005095598A1 (ja) 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド

Also Published As

Publication number Publication date
CA2337743C (en) 2015-07-07
US7517950B2 (en) 2009-04-14
US20060093615A1 (en) 2006-05-04
US20090281043A1 (en) 2009-11-12
CN1178956C (zh) 2004-12-08
US7608685B1 (en) 2009-10-27
CA2337743A1 (en) 2000-02-10
JP2010059172A (ja) 2010-03-18
HK1038929A1 (en) 2002-04-04
US9403886B2 (en) 2016-08-02
EP1103564A4 (en) 2005-02-02
US20090143291A1 (en) 2009-06-04
PT1103564E (pt) 2009-03-13
EP2280031A1 (en) 2011-02-02
US7030212B1 (en) 2006-04-18
US20050266014A1 (en) 2005-12-01
HK1038929B (zh) 2005-05-06
WO2000006602A1 (fr) 2000-02-10
CN102198266A (zh) 2011-09-28
BRPI9912663B1 (pt) 2011-05-31
CN100560130C (zh) 2009-11-18
HK1153761A1 (en) 2012-04-05
EP1103564A1 (en) 2001-05-30
JP4422903B2 (ja) 2010-03-03
US20160243209A1 (en) 2016-08-25
HK1130069A1 (en) 2009-12-18
BRPI9912663A (pt) 2001-05-02
AU4932199A (en) 2000-02-21
ATE420112T1 (de) 2009-01-15
EP2048160B1 (en) 2015-01-07
CN1560078A (zh) 2005-01-05
JP5230579B2 (ja) 2013-07-10
CN1560078B (zh) 2011-06-22
HK1036073A1 (en) 2001-12-21
EP2280031B1 (en) 2015-04-15
DK1103564T3 (da) 2009-05-11
EP2048160A1 (en) 2009-04-15
DE69940264D1 (de) 2009-02-26
KR100767554B1 (ko) 2007-10-17
ES2318898T3 (es) 2009-05-01
US7390871B2 (en) 2008-06-24
CN1762490A (zh) 2006-04-26
US7807792B2 (en) 2010-10-05
EP1103564B1 (en) 2009-01-07
KR20010072112A (ko) 2001-07-31
CN1314916A (zh) 2001-09-26

Similar Documents

Publication Publication Date Title
BRPI9912663B1 (pt) vacina contra cáncer e polipeptìdeo.
DK1200418T3 (da) Nematodicide trifluorbutener
NO990025D0 (no) Hamster-EF-1<alfa> transkripsjonsregulatorisk DNA
ATE196164T1 (de) Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend
DE69902998D1 (de) Dentalschleifmittel
NO20004758L (no) Vaksinesammensetning
DK0601154T3 (da) BPC-peptider, deres fremstilling og anvendelse
ATE297761T1 (de) Zubereitungen zur stabilisierung von peg- interferon alpha konjugaten
BR0011469A (pt) Gm-csf equina
SE9602822D0 (sv) New receptor
CY2008005I1 (el) Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn
NO20005599L (no) Vaksine
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
ATE305517T1 (de) Neurotrypsin
PE20399A1 (es) Muteina ob
ATE295182T1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
LV12722A (lv) Prv-1 gene and the use thereof
DE69940952D1 (de) Gen eines menschlichen lysozyms, davon kodiertes p
SE0101519D0 (sv) Nucleic ACID
BR0107799A (pt) Proteìna de interação de wt1 wtip
ES1042138Y (es) Corona funeraria.
ID20760A (id) Etermanan atau karboksimetilmanan natrium
ITMI981384A0 (it) Vaccino per hiv
SE9903897D0 (sv) Dot dot code